132224-93-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Cyano-Phenyl)ethylamine is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of drug molecules with different therapeutic properties.
Used in Polymer Industry:
In the polymer industry, 2-(4-Cyano-Phenyl)ethylamine is used as a monomer or a component in the production of polymers. Its incorporation into polymer chains can impart specific characteristics, such as improved strength or chemical resistance, to the final product.
Used in Dye Industry:
2-(4-Cyano-Phenyl)ethylamine is used as a precursor in the synthesis of dyes. Its presence in the dye molecules can contribute to the color properties and stability of the dyes, making them suitable for various applications, such as textiles, plastics, and printing inks.

InChI:InChI=1/C9H10N2/c10-6-5-8-1-3-9(7-11)4-2-8/h1-4H,5-6,10H2

Upstream product

• 172348-86-6 tert-butyl N-[2-(4-cyanophenyl)ethyl]carbamate 
• 136918-14-4 phthalimide 
• 69395-13-7 4-(2-hydroxyethyl)benzonitrile 
• 1972-28-7 diethylazodicarboxylate 
• 191170-76-0 benzyl N-[2-(4-bromophenyl)ethyl]carbamate 
• 126158-10-9 4-(2-nitroethyl)benzonitrile 
• 3156-42-1 4-[(E)-2-nitroethenyl]benzonitrile 
• 105-07-7 4-cyanobenzaldehyde 
• 501-53-1 benzyl chloroformate 
• 167762-80-3 4‐(2‐aminoethyl)benzonitrile hydrochloride 
• 714568-47-5 4-(2-azidoethyl)benzonitrile 

Downstream Products

• 714568-34-0 2-[4-(4,5-dihydro-1H-imidazol-2-yl)-phenyl]-ethylamine 
• 791839-12-8 [2-(4-carbamimidoyl-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 172348-86-6 tert-butyl N-[2-(4-cyanophenyl)ethyl]carbamate 
• 1612182-84-9 4-(2-{[2-amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)benzonitrile 
• 1440515-00-3 C₁₄H₁₃N₃O₂S 

Relevant academic research and scientific papers

TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS

The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyp

Ruthenium(II)-cored supramolecular organic framework-mediated recyclable visible light photoreduction of azides to amines and cascade formation of lactams

Ru(bpy)3]2+-cored supramolecular organic framework SMOF-1, assembled from a [Ru(bpy)3]2+-derived hexaarmed molecule and cucurbit[8]uril, has been demonstrated to heterogeneously catalyze visible light-induced reduction of phenyl, benzyl, 2-phenylethyl and 3-phenylpropyl azides in acetonitrile to produce the corresponding amines in good to high yields. For the last two kinds of azides that bear a CO2Me group at the para-position of the benzene ring, cascade reactions take place to generate the corresponding lactams in high yields. Compared with homogeneous control [Ru(bpy)3]Cl2, SMOF-1 exhibits remarkably increased photocatalysis activity as a result of synergistic effect of the [Ru(bpy)3]2+ units that form cubic cages to host the azide molecules and related intermediates. Moreover, SMOF-1 displays high recyclability and considerable photocatalysis activity after 3 to 12 runs.

Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines

The serine protease, PACE4, is a proprotein convertase that plays a substantial role in malignancy of prostate cancer. Our initial selective PACE4 inhibitor (Ac-LLLLRVKR-NH2) has evolved to the current lead compound C23 (Ac-dLeu-LLLRVK-Amba), w

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is -NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

Methods and compositions for treating pain

The present application relates to compounds and methods for treating pain, incontinence and other conditions.

DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

The invention relates to derivatives of 2-aminothiazoles and 2-aminooxazoles in all its stereoisomeric forms, enantiomeric forms and mixtures in any ratio, and its physiologically acceptable salts and tautomeric forms showing PPARdelta agonist activity. W

NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS

The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

2-QUINOXALINONE DERIVATIVES AS BRADYKININ ANTAGONISTS AND NOVEL COMPOUNDS

2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use

The present invention relates to novel N-(phenylsulphonyl)glycyl-glycine compounds, which are defined by formula I and the description, as well as their method of preparation and their use in therapeutics

4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.